Lumateperone PLGA Microspheres for Stable Sustained Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Lumateperone long-acting formulations face challenges in achieving minimal burst release and stable release, which are crucial for effective treatment of schizophrenia symptoms and adherence to medication schedules, while existing methods do not adequately address these issues.
Innovation Solution
A Lumateperone pharmaceutical composition using a glycolide-lactide copolymer (PLGA) with controlled degradation rates, combined with a specific weight ratio of Lumateperone to the pharmaceutical excipient, is formulated into long-acting microspheres through methods like homogeneous emulsification and microfluidic technology to achieve sustained release for one week to two months.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Lumateperone long-acting formulations are developed, then patient compliance and treatment effectiveness are improved, but achieving minimal burst release and stable release characteristics remains challenging
Solution Approach 1:
The patent systematically varies critical parameters including PLGA polymer molecular weight (5,000-120,000 Daltons), lactic acid to glycolic acid molar ratios (95:5 to 50:50), and drug-to-polymer weight ratios to optimize the release profile. These parameter changes enable control over degradation rate and burst release characteristics while maintaining treatment effectiveness.
Solution Approach 2:
The formulation employs composite material systems combining Lumateperone with PLGA polymers of different molecular weights and compositions. This composite approach allows tuning of release kinetics by selecting specific polymer combinations, achieving both minimal burst release and stable sustained release over 1-2 months.
2Speed
If the degradation rate of the polymer is increased to achieve faster drug release, then the onset of action is improved, but the sustained release duration is reduced
Solution Approach 1:
The patent divides the polymer system into segments with different degradation rates by combining PLGA polymers of various molecular weights and lactic acid to glycolic acid ratios. This segmentation allows the formulation to provide both rapid initial release (onset of action) and prolonged sustained release by having faster-degrading and slower-degrading polymer segments working in combination.
3Productivity
If the drug loading concentration is increased to reduce injection volume, then the formulation efficiency is improved, but the uniformity and stability of release are compromised
Solution Approach 1:
The patent optimizes the drug-to-polymer weight ratio parameter within specific ranges to achieve balanced drug loading. By carefully controlling this parameter along with polymer molecular weight and composition, the formulation achieves both high formulation efficiency (reduced injection volume) and uniform stable release characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation ensures stable and effective drug release, improving patient compliance and safety, and addresses the challenges of burst release and uniformity in existing Lumateperone formulations.
Implementation Method 1
a glycolide-lactide copolymer (PLGA) with a weight-average molecular weight (Mw) of 5,000 to 120,000 Daltons; and in the glycolide-lactide copolymer, a molar ratio of lactic acid units to glycolic acid units is 95:5 to 50:50
Implementation Method 2
formulated into long-acting microspheres through methods like homogeneous emulsification and microfluidic technology
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to the field of pharmaceutical formulations. Disclosed are a composition containing Lumateperone active ingredients, and a long-acting sustained-release formulation and a preparation method therefor. A composition containing Lumateperone active ingredients capable of achieving long-acting sustained release is obtained by means of a specific definition on medicinal polymer auxiliary materials; and preparation process conditions are further controlled to obtain a long-acting sustained-release formulation containing Lumateperone active ingredients, so that the sustained release of Lumateperone is implemented in one week to two months, and compared with general formulations (for example: capsules), the compliance of patients can be effectively improved; and clinical requirements of stable drug release are satisfied while the drug safety and effectiveness are ensured.